Elmind Capital LP Makes New $26.72 Million Investment in Viridian Therapeutics, Inc. $VRDN

Elmind Capital LP acquired a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 4th quarter, HoldingsChannel reports. The firm acquired 858,631 shares of the company’s stock, valued at approximately $26,721,000. Viridian Therapeutics makes up 7.9% of Elmind Capital LP’s portfolio, making the stock its 3rd largest position.

Several other institutional investors and hedge funds have also bought and sold shares of VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after buying an additional 876 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Viridian Therapeutics by 12.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after buying an additional 14,788 shares during the period. Envestnet Asset Management Inc. purchased a new stake in Viridian Therapeutics in the 2nd quarter worth approximately $187,000. Finally, Creative Planning bought a new position in shares of Viridian Therapeutics in the 2nd quarter worth approximately $179,000.

Insiders Place Their Bets

In related news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the transaction, the director directly owned 5,090,928 shares in the company, valued at approximately $86,545,776. This represents a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.40% of the stock is currently owned by company insiders.

Viridian Therapeutics Stock Up 4.6%

VRDN stock opened at $16.71 on Thursday. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.72 billion, a PE ratio of -5.03 and a beta of 0.90. The business has a 50 day moving average of $15.91 and a 200 day moving average of $24.92.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. During the same quarter last year, the company earned ($0.87) EPS. The firm’s revenue for the quarter was up 95.8% on a year-over-year basis. On average, research analysts forecast that Viridian Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on VRDN shares. Evercore set a $26.00 target price on Viridian Therapeutics in a research report on Friday, May 15th. HC Wainwright decreased their target price on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Royal Bank Of Canada increased their target price on Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Wells Fargo & Company decreased their target price on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, May 5th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.